Title: US Food and Drug Administration’s Review of the Novel Antidepressant Vortioxetine
Abstract: Article Abstract Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text. he article by Zhang and colleagues in this issue of The Journal of Clinical Psychiatry provides a concise summary of the evidence reviewed by the US Food and Drug Administration (FDA) as part of its evaluation of the novel antidepressant vortioxetine. The article also offers some insights into the FDA's decision-making process that led to the drug's approval and their recommendations for further studies. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, vortioxetine is one of the newer options available for this important area of therapeutics.